Healthcare Stocks Gaining; GSK/Pfizer Joint Venture Picks Up FDA Nod For HIV Drug

Comment

Shutterstock photo

Top Healthcare Stocks

JNJ +1.2%

PFE +0.1%

ABT +0.1%

MRK -0.1%

AMGN +0.3%

Healthcare stocks are higher with the NYSE Healthcare Sector Index rising 0.4% and shares of healthcare companies in the S&P 500 adding 0.5% as a group.

In company news, GlaxoSmithKline ( GSK ) is up 1.3% to near $52 a share after the U.S. Food and Drug Administration today approved its ViiV Healthcare joint venture with Pfizer Inc ( PFE ) that's been developing a new HIV treatment.

The agency has approved Tivicay 50-mg tablets, which is an integrase inhibitor to be combined with other drugs to treat HIV-1 in adults and children aged 12 years and older weighing at least 88 pounds.

GSK and PFE formed ViiV in 2009. PFE is slightly higher at near $29.20 a share, up 0.1%.

In other sector news,

(+) AVNR, (+4.2%, near 52 week highs) Enters exclusive, multi-year deal with Merck ( MRK ) to co-promote MRK's type 2 diabetes therapies. The package is worth up to $60 mln over the next three years, AVNR said.

(-) MDCO, (-4%) Discloses plans to sell up to 5.5 mln shares of its common stock through an underwritten public offering of stock.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.



This article appears in: Investing , Commodities
More Headlines for: GSK , MRK , PFE


More from MT Newswires

Subscribe






MT Newswires
Contributor:

MT Newswires

Market News, Commodities
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com